Janssen
DARZALEX
Manufacturer:
Janssen
Name:
DARZALEX
HCPCS Code Descriptor:
Injection, daratumumab, 10 mg
Category:
J Code
HCPCS:
J9145
NDC(s):
57894-0502-20, 57894-0502-05
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
DARZALEX is an Oncology drug manufactured by Janssen and administered via the Intravenous route of administration. The J Code: J9145 is aligned to the drug DARZALEX.
Access Pricing and More By Registering
HCPCS Added Date:
1/1/17
HCPCS Effective Date:
1/1/17
HCPCS Short Description:
Injection, daratumumab 10 mg
Billing and Coding Guide:
https://www.janssencarepath.com/hcp/sites/www.janssencarepath-v2.com.hcp/files/darzalex-faspro-reimbursement-and-access-guide.pdf?v=128
Patient Assistance:
http://www.jjpaf.org/